About the Company
NeurAxis, Inc
BUSINESS DESCRIPTION
NeurAxis is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. NeurAxis is dedicated to advancing the science with its’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. We believe that superior science, evidence-based research, and building on its unparalleled body of clinical evidence is necessary for adoption by the medical...
NeurAxis, Inc News
-
NeurAxis Inc. Issues Letter to Shareholders...
01/13/2025 02:00 PMCARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commer...
-
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results...
01/08/2025 02:00 PMRevenues in 4Q24 increased approximately 50% versus 4Q23Cash balance as of 12/31/24 was approximately $3.7 million CARMEL, Ind., Jan. 08, 2025 (GLOBE NEWSWIRE) ...
-
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Sum...
01/06/2025 02:00 PMCARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commer...
-
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation o...
12/10/2024 02:00 PMRED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual sensation testing devices without needing electronics...
-
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage...
11/15/2024 04:46 PMNRXS reports strong third-quarter results with rising revenues, reduced losses and expanded insurance coverage, driving its stock to outperform the market....
-
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Inc...
11/12/2024 01:10 PMConference call will be held today, Tuesday, November 12 at 9:00 am ETCARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “...
-
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday,...
11/05/2024 02:00 PMCARMEL, Ind., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commer...
-
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressabl...
11/04/2024 02:00 PMClearance expands indication for use from 11-18 year olds to 8-21 year olds; and from 3 devices, not to exceed 4 weeks, to 1 device per week for 4 weeksCARMEL, ...
-
NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effecti...
10/29/2024 01:00 PMCARMEL, Ind., Oct. 29, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commer...
Disclaimer: